Hinova Pharmaceuticals (SH:688302) Di Yi Cai Jing·2025-05-30 10:52Group 1 - The National Medical Products Administration approved the listing of the innovative drug Deuteroenzalutamide capsules (brand name: Hainaanan®) developed by Haichuang Pharmaceutical, providing a new treatment option for adult patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after receiving abiraterone acetate and chemotherapy [1][4][6] - The approval marks a significant milestone for Haichuang Pharmaceutical, representing 12 years of innovative research and development, and is the first small molecule innovative drug approved in Chengdu Tianfu International Bio-city [2][3][4] - Deuteroenzalutamide is an androgen receptor (AR) inhibitor developed based on Haichuang's core deuterated drug platform and has received support from the National Major New Drug Creation Technology Major Project [4][6] Group 2 - Prostate cancer is the fifth most common cancer among men in China, with an increasing incidence rate. It is estimated that by 2024, there will be 160,000 new cases of mCRPC in China, rising to 176,000 by 2030 [6] - The launch of Deuteroenzalutamide fills a clinical gap as there were no approved AR inhibitors for this indication in China prior to its approval [6][11] - Haichuang Pharmaceutical plans to enhance academic promotion efforts to increase awareness of the product among doctors and patients, aiming to improve patient survival rates and quality of life [7][11] Group 3 - Chengdu Tianfu International Bio-city has established a complete biopharmaceutical ecosystem from research and development to industrialization, supporting the growth of innovative pharmaceutical companies [2][8] - The bio-city provides comprehensive lifecycle services for enterprises, including streamlined approval processes, financial and market activities, and shared facilities to reduce collaboration costs [8][10] - The bio-city has also implemented green energy solutions, such as distributed photovoltaic projects, to ensure stable energy supply for biopharmaceutical enterprises [10] Group 4 - Haichuang Pharmaceutical has six additional products in various stages of clinical trials and several in preclinical research, indicating a robust product pipeline [11] - The company emphasizes sustainable and healthy development, focusing on long-term strategic planning to benefit more patients with new drug developments [11][12] - Chengdu Tianfu International Bio-city aims to continue fostering high-level innovation and support the biopharmaceutical industry’s high-quality development through comprehensive policy guarantees and resource mobilization [12][13]